B02BD01 • coagulation factors • Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors
Coagulation factors are essential proteins involved in the process of stopping bleeding, playing a key role in blood clot formation. Deficiency or dysfunction of these factors can lead to bleeding disorders such as hemophilia or von Willebrand disease. Treatment with coagulation factors is used to prevent or stop bleeding in people with such conditions.
Coagulation factors are administered intravenously under medical supervision, with the dose determined by the severity of the deficiency and the type of bleeding event. Treatment can be given preventively or as needed, for example during surgeries or after injuries.
Side effects may include allergic reactions, fever, headaches, or, rarely, the development of antibodies that can reduce the effectiveness of the treatment. Careful monitoring of the patient is essential to quickly detect any adverse reactions and adjust the treatment if necessary.
Therapy with coagulation factors has significantly improved the quality of life for patients with bleeding disorders. Following medical advice and being informed about possible risks contribute to safe and effective treatment.
Substance: coagulation factors
Date of last drug list: 01-05-2026
Commercial code: W65359002
Concentration: 500UI
Pharmaceutical form: powder+solvent for solution for infusion
Quantity: 1
Product type: original
Price: 1199.42 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: OCTAPHARMA PHARMAZEUTIKA PROD. GES.M.B.H. - AUSTRIA
Holder: OCTAPHARMA (IP) SPRL - BELGIA
Number: 7802/2015/01
Shelf life: 3 years